Jiankang Yuan (600380.SH) subsidiary company receives approval letter for drug clinical trial.

Wisdom Finance App News, Jiankangyuan (600380.SH) announced that recently, the holding subsidiary of the company, Lizhu Pharmaceutical Group Co., Ltd., received the approved "Drug Clinical Trial Approval Notice" (Notification Numbers: 2025LP03436, 2025LP03437) issued by the National Medical Products Administration for NS-041 tablets to add the indication of "treating depression". The company's subsidiary Lizhu Pharmaceutical Factory is now authorized to conduct clinical trials for the new indication of NS-041 tablets.